Dr. Scott is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 855-557-0555Fax+1 206-606-1025
Education & Training
University of WashingtonFellowship, Medical Oncology, 1999 - 2000
University of South Alabama College of MedicineClass of 1996
Certifications & Licensure
WA State Medical License 1999 - 2026
MD State Medical License 2000 - 2001
Clinical Trials
- Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
- Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome Start of enrollment: 2017 Mar 02
Publications & Presentations
PubMed
- 20 citationsImpact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemiaJanghee Woo, Dae Ro Choi, Barry E. Storer, Cecilia Yeung, Anna B. Halpern
Haematologica. 2020-03-01 - 22 citationsA prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantationNico Gagelmann, Anita Badbaran, Dietrich W. Beelen, Rachel B. Salit, Friedrich Stölzel
Blood Advances. 2021-03-23 - 138 citationsHematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential ThrombocythemiaDaniella M. B. Kerbauy, Ted Gooley, George E. Sale, Mary E.D. Flowers, Kristine Doney
Biology of Blood and Marrow Transplantation. 2007-03-01
Journal Articles
- Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica
- Recipient Single Nucleotide Polymorphisms in Paneth Cell Antimicrobial Peptide Genes and Acute Graft‐Versus‐Host Disease: Analysis of BMT CTN‐0201 and ‐0901 SamplesArmin Rashidi, Edmund K Waller, Bharat Thyagarajan, Claudio Anasetti, Daniel J Weisdorf, Bart L Scott, Bruce R Blazar, British Journal of Haematology
Abstracts/Posters
- Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...Bart L. Scott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele BurdenBart L. Scott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) ...Bart L. Scott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Ch...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Successes in Bone Marrow Failures - 2011 ASH SatelliteCleveland Clinic - Cleveland, Ohio / The Cleveland Clinic Foundation, San Diego, California - 12/9/2011
Press Mentions
Fred Hutch at ASCO: New Insights on Financial Toxicity, Combination Therapies for Cancer and the Need for Targeted Breast Cancer Therapies in UgandaMay 26th, 2023- Column: We Pray for Damar Hamlin — and Then Settle Back in for More FootballJanuary 8th, 2023
Myeloablative Therapy Prevails in AML Transplant StudyFebruary 21st, 2020- Join now to see all
Grant Support
- Improving Allogenic Transplant Outcomes In Myeloid MalignanciesNational Heart, Lung, And Blood Institute2007–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
